Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
India trial finds limited effectiveness from convalescent plasma
Fri October 23rd - Using convalescent plasma to treat moderately ill COVID-19 patients did not reduce severity of the illness or risk of death, according to the findings of a small clinical trial published today. More
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...

Cholesterol drug combinations best to reduce cardiovascular risk

Tuesday September 1st 2020

People who have the highest risk of cardiovascular problems could benefit being prescribed lipid-lowering therapies, a major conference – held on-line – has heard.

The new study, presented to the virtual meeting of the European Society of Cardiology (ESC) and published in the European Journal of Preventive Cardiology, highlights a gap between existing clinical guidelines and clinical practice for cholesterol management across Europe.

The DA VINCI study, led by Imperial Clinical Trials Unit at Imperial College, London, UK, analysed data from 5888 patients in 18 countries about the management of their cardiovascular conditions.

The researchers found that 84% of patients received statins as their primary lipid-lowering therapy only, with high intensity statins used by 28% of patients.

Just 9% of patients were prescribed ezetimibe with moderate intensity statins and 1% were prescribed PCSK9 inhibitors in combination with statins and/or ezetimibe.

Current guidelines from the ESC and European Atherosclerosis Society (EAS) recommend statins as first-line treatment for lowering LDL cholesterol and they also recommend goals based on risk groupings, such as a target of 50% reduction in cholesterol-lowering (LDL-C) goals in very-high risk patients and achieving LDL-C levels below 1.4mmol/L, in order to reduce the risk of additional cardiovascular events.

They found that 22% of patients who took high-intensity statins achieved the 2019 LDL-C goals, while about two thirds of those who had statins with a PCSK9 inhibitor attained them.

The study authors say the findings highlight the potential for combinations of lipid lowering drugs to help close the gap and reduce the risk for millions of patients across Europe.

Reducing LDL cholesterol levels in very-high risk patients could result in an 11% relative reduction in cardiovascular events and 5% relative reduction in mortality, they add.

Professor Kausik Ray from Imperial's School of Public Health in London, who led the DA VINCI study, said: “In order to tackle the burden of cardiovascular disease, a global approach is needed. After diet and lifestyle, cholesterol lowering with medications is a key approach to lowering risk of heart disease and strokes.

“Based on trial data we have compelling evidence that lower cholesterol levels benefit those at highest risk particularly.

“Though statins are first line treatment, it is clear from our contemporary study that statins alone even when optimally used will not help the majority of patients achieve European Society of Cardiology cholesterol goals.

“Only one in five very-high risk patients achieve 2019 recommended goals and to improve this will require use of combination therapy of more than one drug.”

The study used high-intensity statin as a proxy because untreated lipid levels were not available and the authors caution that physician choice of LLT, pre-treatment LDL cholesterol levels and local prescribing restrictions could have influenced their observations.

Ray K et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care - the DA VINCI study. European Journal of Preventive Cardiology 28 August 2020.

Tags: Europe | Heart Health | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)